TABLE 2.
Paritaprevir pharmacokinetics in plasma and in liver tissue samples from rats receiving 30-mg/kg dosesa
| Paritaprevir pharmacokinetic parameter | Value |
|||||
|---|---|---|---|---|---|---|
| Plasmab | Tissue samplesc |
|||||
| Surgical resection | CNB | FNA5 | FNA3 | FNA1 | ||
| Tmax (h) | 2.1 | 2.1 | 5.5 | 2.1 | 2.1 | 2.1 |
| Cmax (ng/ml) | 3,593 | 125,076 | 100,412 | 75,125 | 47,368 | 56,628 |
| AUC0–24 (ng · h/ml) | 3,970 | 394,315 | 373,533 | 235,290 | 205,036 | 144,949 |
| t1/2 (h) | 5.0 | 3.0 | 4.1 | 5.2 | 6.1 | 4.7 |
One rat (corresponding to the 4-h time point) was excluded from these analyses because paritaprevir was not at steady state. Abbreviations: CNB, core needle biopsy; FNA1, fine-needle aspiration with 1 pass; FNA3, fine-needle aspiration with 3 passes; FNA5, fine-needle aspiration with 5 passes; AUC, area under the concentration-time curve; Cmax, maximum observed concentration; t1/2, half-life; Tmax, time of maximum observed concentration.
The plasma concentrations corresponding to 24 and 25 h postdose were below the assay's lower limit of quantitation, and their values were thus set at 0.625 ng/ml.
Concentrations measured in tissue samples were converted from nanograms per gram to nanograms per milliliter by using a liver tissue density value for rats of 1.05 g/ml (32).